Study patient characteristics
| Variable . | LBCL . | FL . | MCL . | P value . |
|---|---|---|---|---|
| n | 191 | 20 | 25 | |
| Age at apheresis, median (IQR) | 63 (55-71) | 60.50 (53-69.25) | 68 (65-73) | .025 |
| Sex = female, n (%) | 81 (42.4) | 7 (35.0) | 6 (24.0) | .188 |
| ECOG, n (%) | .277 | |||
| 0 | 41 (21.5) | 1 (5.0) | 3 (12.0) | |
| 1 | 133 (69.6) | 17 (85.0) | 21 (84.0) | |
| 2+ | 17 (8.9) | 2 (10.0) | 1 (4.0) | |
| Identifies as Hispanic = Yes, n (%) | 29 (15.2) | 6 (30.0) | 2 (8.0) | .119 |
| Stage at apheresis, n (%) | .019 | |||
| 1 | 24 (12.6) | 0 (0.0) | 0 (0.0) | |
| 2 | 24 (12.6) | 1 (5.0) | 1 (4.0) | |
| 3 | 19 (9.9) | 6 (30.0) | 3 (12.0) | |
| 4 | 124 (64.9) | 13 (65.0) | 21 (84.0) | |
| Prior auto transplant, n (%) | 43 (22.5) | 2 (10.0) | 8 (32.0) | .213 |
| Prior systemic lines, median (IQR) | 3 (2-4) | 4.50 (3-7.25) | 4 (3, 6) | <.001 |
| Normalized pre-LD LDH, median (IQR) | 1.10 (0.84-1.49) | 1.05 (0.88-1.32) | 0.90 (0.82-1.26) | .334 |
| ALC at leukapheresis, median (IQR) | 0.78 (0.50-1.12) | 0.76 (0.58-1.19) | 1.17 (0.50-1.64) | .409 |
| COO = non-GCB, n (%) | 77 (42.1) | NA | NA | |
| Histology, n (%) | ||||
| DLBCL | 110 (57.6) | NA | NA | |
| HGBCL | 36 (18.8) | NA | NA | |
| TFL | 32 (16.8) | NA | NA | |
| Other LBCL | 13 (6.8) | NA | NA | |
| History of CNS disease, n (%) | 14 (7.3) | 0 (0.0) | 3 (12.0) | .299 |
| Variable . | LBCL . | FL . | MCL . | P value . |
|---|---|---|---|---|
| n | 191 | 20 | 25 | |
| Age at apheresis, median (IQR) | 63 (55-71) | 60.50 (53-69.25) | 68 (65-73) | .025 |
| Sex = female, n (%) | 81 (42.4) | 7 (35.0) | 6 (24.0) | .188 |
| ECOG, n (%) | .277 | |||
| 0 | 41 (21.5) | 1 (5.0) | 3 (12.0) | |
| 1 | 133 (69.6) | 17 (85.0) | 21 (84.0) | |
| 2+ | 17 (8.9) | 2 (10.0) | 1 (4.0) | |
| Identifies as Hispanic = Yes, n (%) | 29 (15.2) | 6 (30.0) | 2 (8.0) | .119 |
| Stage at apheresis, n (%) | .019 | |||
| 1 | 24 (12.6) | 0 (0.0) | 0 (0.0) | |
| 2 | 24 (12.6) | 1 (5.0) | 1 (4.0) | |
| 3 | 19 (9.9) | 6 (30.0) | 3 (12.0) | |
| 4 | 124 (64.9) | 13 (65.0) | 21 (84.0) | |
| Prior auto transplant, n (%) | 43 (22.5) | 2 (10.0) | 8 (32.0) | .213 |
| Prior systemic lines, median (IQR) | 3 (2-4) | 4.50 (3-7.25) | 4 (3, 6) | <.001 |
| Normalized pre-LD LDH, median (IQR) | 1.10 (0.84-1.49) | 1.05 (0.88-1.32) | 0.90 (0.82-1.26) | .334 |
| ALC at leukapheresis, median (IQR) | 0.78 (0.50-1.12) | 0.76 (0.58-1.19) | 1.17 (0.50-1.64) | .409 |
| COO = non-GCB, n (%) | 77 (42.1) | NA | NA | |
| Histology, n (%) | ||||
| DLBCL | 110 (57.6) | NA | NA | |
| HGBCL | 36 (18.8) | NA | NA | |
| TFL | 32 (16.8) | NA | NA | |
| Other LBCL | 13 (6.8) | NA | NA | |
| History of CNS disease, n (%) | 14 (7.3) | 0 (0.0) | 3 (12.0) | .299 |
Patients are representative of prior reported cohorts and have similar outcomes to those reported in major studies and large consortia analysis. P values as assigned by unadjusted Kruskal-Wallis test.
ALC, absolute lymphocyte count; CNS, central nervous system; COO, cell of origin; ECOG, Eastern Cooperative Oncology Group; GCB, germinal center B-cell; IQR, interquartile range; LD, lymphodepletion; NA, not available.